TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response

Chiao‐En Wu(Chang Gung University), John Lunec(Newcastle University)

Cancer Cell International

March 7, 2019

10.1186/s12935-019-0768-3

Cited by 11

Related Papers

Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma

|British Journal of Cancer|2017|63

Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2

|British Journal of Cancer|2004|53

ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma

|Cancers|2018|39

<i>TP53</i> mutant <i>MDM2</i>-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation

|Oncotarget|2016|21

Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients

|BMC Cancer|2020|16